A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Sponsor
- National University Hospital, Singapore
- Enrollment
- 33
- Locations
- 1
- Primary Endpoint
- Difference in tolerance scores in cancer patients, over the duration of a limb cryocompression cycle, as assessed by Visual Analogue Scale for pain
- Last Updated
- 4 years ago
Overview
Brief Summary
The study aims to investigate the safety and tolerability of limb cryocompression in preventing of Chemotherapy-induced Peripheral Neuropathy via a newly developed limb cryocompression device in healthy subjects and cancer patients. The limb cryocompression device will be tested for its safety in delivering limb cryocompression and efficacy in improving the preservation of peripheral nerves during chemotherapy.
Detailed Description
The study consists of two parts. The first part of the study will consist of up to 18 healthy subjects to assess safety and tolerability of the new limb cryocompression device. The occurrence or lack of core hypothermia will be studied. The second part of the study will consist of 15 cancer patients recruited from the National University Hospital. Patients will undergo cryocompression over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy. Cryocompression of the limbs will be administered using cooling wraps attached to a cooling device. The limbs will be cooled from the digits to the elbow/knee.
Investigators
Eligibility Criteria
Inclusion Criteria
- •For healthy subjects:
- •Age 21-80 years
- •Signed informed consent from patient or legal representative
- •No history of neuropathy
- •No history of hospitalization in the past 6 months
- •For cancer patients:
- •Age 21- 80 years
- •Signed informed consent from patient or legal representative
- •Scheduled to receive weekly paclitaxel chemotherapy
- •Patients may receive other chemotherapy drugs alongside taxane e.g. Platinum/Herceptin.
Exclusion Criteria
- •For healthy subjects:
- •Open skin wound or ulcers of the limbs
- •History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes
- •Pregnant women
- •For cancer patients:
- •Open skin wound or ulcers of the limbs
- •History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes
- •Pregnant women
Outcomes
Primary Outcomes
Difference in tolerance scores in cancer patients, over the duration of a limb cryocompression cycle, as assessed by Visual Analogue Scale for pain
Time Frame: During every cycle of paclitaxel chemotherapy (each cycle is 1 week) along with cryocompression which may last up to 4 hours, and for up to 12 cycles of weekly Paclitaxel treatment
Defined as the number of patients with treatment-related intolerance as assessed by tolerability scale, visual analog scale (VAS). On a scale of 0 to 10, a higher VAS score indicates higher intolerance. A score of 8 out of 10 will be considered dose-limiting intolerance.
Difference in tolerance scores in healthy volunteers, over the duration of a limb cryocompression cycle, as assessed by Visual Analogue Scale for pain
Time Frame: During limb cryocompression procedure, 3 hours for healthy subject
Defined as the number of subjects with treatment-related intolerance as assessed by tolerability scale, visual analog scale (VAS). On a scale of 0 to 10, a higher VAS score indicates higher intolerance. A score of 8 out of 10 will be considered dose-limiting intolerance.
Incidence of Treatment-Emergent Adverse Events in healthy volunteers, over the duration of a limb cryocompression cycle, as assessed by Common Terminology Criteria for Adverse Events 5.0
Time Frame: During limb cryocompression procedure, 3 hours for healthy subject
Defined as the number of subjects with treatment-related adverse events as assessed by CTCAE v5.0. Grade 1-5 refer to the severity of the adverse event with higher grade indicating greater severity. Grade 3 and above will be considered severe.
Incidence of Treatment-Emergent Adverse Events in cancer patients, over the duration of a limb cryocompression cycle, as assessed by Common Terminology Criteria for Adverse Events 5.0
Time Frame: During every cycle of paclitaxel chemotherapy (each cycle is 1 week) along with cryocompression which may last up to 4 hours, and for up to 12 cycles of weekly Paclitaxel treatment
Defined as the number of patients with treatment-related intolerance as assessed by CTCAE v5.0. Grade 1-5 refer to the severity of the adverse event with higher grade indicating greater severity. Grade 3 and above will be considered severe.
Secondary Outcomes
- Difference in tolerance scores between various temperature and pressure using Common Terminology Criteria for Adverse Events 4.0 and Visual Analogue Scale for pain(During limb cryocompression procedure, 3 hours for healthy subject)
- Difference in qualitative symptom scores using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale(Before start of weekly paclitaxel chemotherapy, at the end of 12 cycles of weekly paclitaxel treatment, at 3-, 6-, and 12-months post-treatment)